MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Total revenues | $— | $— | $— |
| Operating expenses: | |||
| Research and development | 272,350 | 245,441 | 205,164 |
| General and administrative | 108,146 | 48,130 | 37,318 |
| Total operating expenses | 380,496 | 293,571 | 242,482 |
| Loss from operations | (380,496) | (293,571) | (242,482) |
| Interest income | 19,578 | 2,185 | 363 |
| Interest expense | (12,712) | (3,964) | — |
| Other income | — | — | 273 |
| Net loss | $(373,630) | $(295,350) | $(241,846) |
| Net loss per common share: | |||
| Basic and diluted net loss per common share | $(19.99) | $(17.23) | $(14.63) |
| Basic and diluted weighted average number of common shares outstanding | 18,687,774 | 17,137,201 | 16,535,188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.